Every material Form 8-K NRX Pharmaceuticals, Inc. has filed with the SEC since October 05, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
NRx Pharmaceuticals said the FDA approved its Abbreviated New Drug Application for Preservative-Free Ketamine ahead of the November 10, 2026 GDUFA goal date. The company says it now has commercial supply on hand to label the product and sell it to American hospitals and clinics, but the filing gives no sales, revenue or earnings figures.
FDA approved the company's ANDA for Preservative-Free Ketamine, announced October 30, 2026, ahead of the November 10, 2026 goal date.
The company says the product contains no benzethonium chloride, a preservative it describes as not GRAS-designated by the FDA.
Manufacturing is with Nephron Pharmaceuticals in West Columbia, South Carolina.
The company says it can now label the product and supply American hospitals and clinics.
NRx Pharmaceuticals set December 17, 2026 as the date for its 2026 annual meeting of stockholders, which will be virtual-only, and October 28, 2026 as the record date for voting. The filing also sets revised deadlines for stockholder proposals and director nominations, which shareholders who want to act at the meeting need to meet.
2026 Annual Meeting: December 17, 2026, 10:00 a.m. Eastern Time, virtual-only by live webcast
Record date for stockholders entitled to vote: October 28, 2026
Rule 14a-8 proposal and advance notice deadline: close of business October 25, 2026
Universal proxy notice deadline under Rule 14a-19: October 26, 2026
On September 29, 2026, subsidiary NRx Defense Systems entered a prime contract with DARPA to conduct the SPARC-TMS clinical trial, which pairs robotic transcranial magnetic stimulation with the investigational drug NRX-101 for treatment-resistant depression. The contract is valued at approximately $11.2 million, with about $6.7 million initially obligated, and the remainder depends on appropriations and DARPA's exercise of funding options.
Aggregate contract value of approximately $11.2 million; approximately $6.7 million initially obligated by DARPA.
18-month performance period, with payment tied to achievement and acceptance of specified milestones.
Either party may terminate under certain circumstances, including if the program is determined unlikely to achieve its objectives.
Full contract terms to be filed as an exhibit to the Form 10-Q for the quarter ending September 30, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every NRX Pharmaceuticals, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →